MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/220/0.1/20.09.24 | Delayed Börse Stuttgart 07:19:28 2024-07-17 am EDT | ||
| 0.01 EUR | -61.54% |
|
| 1 month | -18.75% | ||
| 3 months | -50.00% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
NOVO NORDISK A/S
Latest news about NOVO NORDISK A/S
More news
| Date | Price | Change |
|---|---|---|
| 24-07-17 | 0.01 | -61.54% |
| 24-07-16 | 0.026 | +4.00% |
| 24-07-15 | 0.025 | 0.00% |
| 24-07-12 | 0.025 | +4.17% |
| 24-07-11 | 0.024 | -7.69% |
Delayed Quote Börse Stuttgart
Last update July 17, 2024 at 07:19 am EDT
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | NOVO NORDISK A/S |
| Issuer | Morgan Stanley |
| WKN | ME9ZN1 |
| ISIN | DE000ME9ZN15 |
| Date issued | 2024-03-11 |
| Strike | 220 $ |
| Maturity | 2024-09-20 (65 Days) |
| Parity | 10 : 1 |
| Emission price | 0.16 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.105 € |
|---|---|
| Lowest since issue | 0.007 € |
| Spread | 0.03 € |
| Spread % | 75.00% |
Company Profile
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- diabetes and obesity treatment products (92.6%);
- rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc.
Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Sector
-
Consensus: Novo Nordisk A/S
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
26
Last Close Price
970
DKK
Average target price
956.8
DKK
Spread / Average Target
-1.36%
- Stock Market
- Warrants
- Warrant
